SCHEMBL1033853

SCHEMBL1033853

O=C(Nc1nccs1)c1cccc2ccc(-c3cccnc3)nc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.52
CYP1A2 P05177 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.51
RAB9A P51151 6/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
PKM P14618 2/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
LMNA P02545 1/20 0.50
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
PSMD14 O00487 1/20 0.49
STAMBP O95630 1/20 0.49
COPS5 Q92905 1/20 0.49
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1034301 0.91 HPGD (0.60) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1034289 0.87 NPC1 (0.50) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1036343 0.86 HPGD (0.48) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1075622 0.83 AQP4 (0.57) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1031180 0.83 SIRT2 (0.51) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1034835 0.83 SIRT2 (0.51) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1034198 0.83 NPC1 (0.51) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1033554 0.83 SCN9A (0.53) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1034439 0.83 SIRT2 (0.50) NPC1CYP1A2SIRT2RAB9AMEN1
SCHEMBL1033594 0.83 MAPT (0.62) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 NPC1 3386/4885CYP1A2 2055/4885SIRT2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.